|
Leukoencephalopathy
|
0.030 |
AlteredExpression
|
group |
BEFREE |
GlialCAM expression affects expression of MLC1, ClC-2 and aquaporin4, indicating that abnormal interplay between these proteins is a disease mechanism in megalencephalic leukoencephalopathy with cysts.
|
28695146 |
2017 |
|
Leukoencephalopathy
|
0.030 |
Biomarker
|
group |
BEFREE |
Depolarization causes the formation of a ternary complex between GlialCAM, MLC1 and ClC-2 in astrocytes: implications in megalencephalic leukoencephalopathy.
|
28398517 |
2017 |
|
MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS
|
0.030 |
Biomarker
|
disease |
BEFREE |
Co-expression of the adhesion molecule GlialCAM, which forms a tertiary complex with ClC-2 and megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1), rescued the functional expression of the mutant by modifying its gating properties.
|
28905383 |
2017 |
|
Gestational Diabetes
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Our results showed that ClC-2 mRNA and protein expressions in GDM group were significantly increased in white matter of fetal rats after E18 stage, and elevated the level of TNF-α and iNOS in white matter at P0 and P3 stage of newborn rats.
|
28255270 |
2017 |
|
Chronic idiopathic constipation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women.
|
28849329 |
2017 |
|
Opioid-Induced Constipation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women.
|
28849329 |
2017 |
|
Irritable bowel syndrome with constipation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women.
|
28849329 |
2017 |
|
Parasitic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The involvement of ruminant-specific galectin-11 (LGALS-11) and galectin-14 (LGALS-14) has been postulated to play important roles in protective immune responses against parasitic infection; however, their ligands are unknown.
|
29576976 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
|
29550812 |
2018 |
|
Parasitic infection
|
0.010 |
Biomarker
|
group |
BEFREE |
The involvement of ruminant-specific galectin-11 (LGALS-11) and galectin-14 (LGALS-14) has been postulated to play important roles in protective immune responses against parasitic infection; however, their ligands are unknown.
|
29576976 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
AngII-induced HBVSMC proliferation, migration and invasion were significantly attenuated by ClC-2 downregulation.
|
29988306 |
2018 |
|
Nonalcoholic Steatohepatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ClC-2 mRNA level was significantly increased in patients with non-alcoholic steatohepatitis, which positively correlated with the plasma levels of alanine transaminase (ALT), aspartate transaminase (AST) and insulin.
|
29550812 |
2018 |
|
Miscarriage
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Gal-13 and Gal-14 are primarily expressed by the syncytiotrophoblast at the maternal-fetal interface in the first trimester, and their placental expression is decreased in miscarriages compared to first-trimester controls.
|
31275299 |
2019 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our aim was to investigate the potential role of a ClC-2 chloride channel activator, lubiprostone, which is reported to have beneficial effects on LGS, in the development of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice.
|
31206525 |
2019 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our aim was to investigate the potential role of a ClC-2 chloride channel activator, lubiprostone, which is reported to have beneficial effects on LGS, in the development of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice.
|
31206525 |
2019 |
|
Hyperaldosteronism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In the adrenal, ClC-2 has been demonstrated to localize predominantly to the zona glomerulosa (ZG), and functional analysis suggests that mutations in ClC-2 predispose ZG cells to depolarization, thus leading to calcium influx via activation of voltage-gated calcium channels and increased aldosterone production.
|
30949771 |
2019 |
|
Complete hydatidiform mole
|
0.010 |
Biomarker
|
disease |
BEFREE |
Paraffin-embedded tissues from CHMs and control placentas were used for tissue microarray (TMA) construction, immunohistochemistry, and immunoscoring for galectin-14.
|
31658584 |
2019 |
|
early pregnancy
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, these results show that Gal-13 and Gal-14 already provide an immunoprivileged environment at the maternal-fetal interface during early pregnancy, and their reduced expression is related to miscarriages.
|
31275299 |
2019 |
|
Conn Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We now show that almost all known PA-associated CLCN2 mutations markedly increase ClC-2 chloride currents and generate knock-in mice expressing a constitutively open ClC-2 Cl<sup>-</sup> channel as mouse model for PA.
|
31615979 |
2019 |
|
Familial Hyperaldosteronism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Elevated aldosterone and blood pressure in a mouse model of familial hyperaldosteronism with ClC-2 mutation.
|
31727896 |
2019 |